

## AMENDMENTS TO THE CLAIMS

1. **(Currently amended)** An aqueous liquid preparation comprising, in an aqueous solution, (+)-(S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butyric acid or a pharmacologically acceptable acid addition salt thereof, and a water-soluble metal chloride in a light-stabilizing effective amount of 0.2 w/v% or more.
2. **(Currently amended)** The aqueous liquid preparation of claim 1, wherein the metal chloride has a concentration selected from the range of a lower limit concentration of ~~0.15~~ 0.2 w/v% and an upper limit concentration of 1.5 w/v%.
3. **(Previously presented)** The aqueous liquid preparation of claim 1, wherein the metal chloride is at least one kind selected from sodium chloride, potassium chloride and calcium chloride.
4. **(Previously presented)** The aqueous liquid preparation of claim 1, wherein the (+)-(S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butyric acid or the pharmacologically acceptable acid addition salt thereof has a concentration selected from the range of a lower limit concentration of 0.1 w/v% and an upper limit concentration of 2.0 w/v%.
5. **(Previously presented)** The aqueous liquid preparation of claim 1, which is an acid addition salt of (+)-(S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butyric acid.
6. **(Original)** The aqueous liquid preparation of claim 5, wherein the acid addition salt is monobenzenesulfonate.
7. **(Previously presented)** The aqueous liquid preparation of claim 1, wherein the aqueous liquid preparation has a pH in the range of 4-8.5.
8. **(Previously presented)** The aqueous liquid preparation of claim 1, which is an eye drop.

**9. (Previously presented)** The aqueous liquid preparation of claim 1, which is a nasal drop.

**10. (Previously presented)** An aqueous eye drop comprising, in an aqueous solution, (+)-(S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butyric acid monobenzenesulfonate and sodium chloride at not less than 0.2 w/v% and not more than 0.8 w/v% in a light-stabilizing effective amount.

**11. (Cancelled)**

**12. (New)** The aqueous liquid preparation of claim 1, wherein the metal chloride is at least one kind selected from alkali metal chlorides and alkaline earth metal chlorides.

**13. (New)** An aqueous eye drop comprising (+)-(S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butyric acid or a pharmacologically acceptable acid addition salt thereof, which is light-stabilized with a water-soluble metal chloride at not less than 0.2 w/v%.